Evidence map›Paper›PMID 40801567›Full record

ArticleCells2025

Estradiol Downregulates MicroRNA-193a to Mediate Its Angiogenic Actions.

Lisa Rigassi, Mirel Adrian Popa, Ruth Stiller, Brigitte Leeners, Marinella Rosselli, Raghvendra Krishna Dubey

Abstract read
In one paragraph

Article in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lisa RigassiDepartment of Reproductive Endocrinology, University Hospital Zurich, 8952 Schlieren, Switzerland.
Mirel Adrian PopaInstitute of Cellular Biology and Pathology Nicolae Simionescu, Romanian Academy, 050568 Bucharest, Romania.ORCID 0000-0002-4377-8045
Ruth StillerDepartment of Reproductive Endocrinology, University Hospital Zurich, 8952 Schlieren, Switzerland.
Brigitte LeenersDepartment of Reproductive Endocrinology, University Hospital Zurich, 8952 Schlieren, Switzerland.ORCID 0000-0003-4027-6151
Marinella RosselliDepartment of Reproductive Endocrinology, University Hospital Zurich, 8952 Schlieren, Switzerland.
Raghvendra Krishna DubeyDepartment of Reproductive Endocrinology, University Hospital Zurich, 8952 Schlieren, Switzerland.ORCID 0000-0003-1000-7137

Funding

Swiss Cancer Research Foundation KFS-4125-02-2017" to R.K.D.Swiss National Science Foundation grant number 3200B0-106098/1, 320000-117998/1, 31003A-138067 to R.K.DUniscientia P100-2016
6 · The paper itself

Abstract

Estrogens regulate many physiological processes in the human body, including the cardiovascular system. Importantly, Estradiol (E2) exerts its vascular protective actions, in part, by promoting endothelial repair via induction of endothelial cell (EC) proliferation, migration and angiogenesis. Recent evidence that microRNAs (miRNAs) play an important role in vascular health and disease as well as in regulating Estrogen actions in many cell types. We hypothesize that E2 may mediate its vascular protective actions via the regulation of miRNAs. Following initial screening, we found that E2 downregulates the levels of miR-193a-3p in ECs. Moreover, miR-193a-3p downregulation by miR-193a-3p-antimir mimicked the effects as E2 on EC growth, migration, and capillary formation. Restoring miR-193a-3p levels with mimics after E2 treatment abrogated the vasculogenic actions of E2, suggesting a key role of miR-193a-3p in E2-mediated EC-growth-promoting effects. We further investigated the cellular mechanisms involved and found that miR-193a-3p inhibits angiogenesis by blocking phosphoinositide-3-kinase (PI3K)/Akt-vascular endothelial growth factor (VEGF) and Activin receptor-like kinase 1 (ALK1)/SMAD1/5/8 signaling in ECs, both pathways that are important in E2-mediated vascular protection. Additionally, using reverse transcription polymerase chain reaction (RT-PCR), we demonstrate that E2 downregulates miR-193a-3p in ECs via Estrogen Receptor (ER)α, but not ERβ or G protein-coupled estrogen receptor (GPER). Moreover, these actions occur post-transcriptionally, as the expression of pri-miR-193a-3p was not affected. The anti-angiogenic actions of miR-193a-3p were also observed in in vivo Matrigel implant-based capillary formation studies in ovariectomized mice where E2 induced capillary formation, and these effects were abrogated in the presence of miR-193a-3p, but not in the control mimic. Assessment of miR-193a-3p levels in plasma collected from in vitro fertilization (IVF) subjects with low and high E2 levels showed significantly lower miR-193a-3p levels in responders during the high E2 period. Hence, our findings provide the first evidence that miR-193a-3p mimic inhibits angiogenesis whereas its antimir is angiogenic. Importantly, E2 mediates its regenerative actions on ECs/capillary formation by downregulating endogenous miR-193a-3p expression. Both miR-193a-3p mimic or antimir may represent important therapeutic molecules to prevent or to induce endothelial function in treating pathophysiologies associated with capillary growth.

Indexed as

Down-RegulationEstradiolMicroRNAsNeovascularization, PhysiologicAnimalsCell MovementCell ProliferationHumansHuman Umbilical Vein Endothelial CellsMicePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSignal TransductionVascular Endothelial Growth Factor AEstradiolMicroRNAsMIRN193 microRNA, humanPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktVascular Endothelial Growth Factor Aangiogenesiscardiovascular disordersendothelial cellsestradiolmiRNA-139a

Identifiers

PMID40801567
PMCPMC12346790

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.